Chinese bioprocess solutions provider Duoning Biotechnology Group announced on Tuesday that it has partnered with Branca Bunus Ltd, an Ireland-based biotechnology company specialising in innovative gene delivery technologies.
Under the agreement, the two companies will collaborate on the development, optimisation and application of transfection reagents, with the aim of providing biopharmaceutical customers with innovative transfection reagents through resource sharing, thereby improving the efficiency of biopharmaceutical development in upstream bioprocess.
Branca Bunus will be responsible for the research, development and performance improvement of transfection reagents. This includes scientific research applications involving DNA, siRNA and mRNA transfection, and the production of recombinant proteins, AAV and LV based on the transient transfection of CHO and HEK 293 cells. Duoning will use its established sales network and collaborative sales strategy for upstream process products to comprehensively promote this solution.
Both companies will establish a specialised research and marketing team to optimise the transient transfection process by evaluating the interaction principles of transfection reagents and cell culture media. They will also carry out market research to produce a comprehensive solution for the application of transfection reagents.
Hongfeng Gu, Duoning vice president, said: "The BrPERfect series of transfection reagents from Branca Bunús, combined with Duoning's cell culture media, bioreactors and other products, will offer customers more comprehensive upstream bioprocessing solutions."
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist